Navigation Links
GlaxoSmithKline Presents Innovative Neuroscience Pipeline
Date:12/13/2007

used cholinesterase inhibitor, to placebo demonstrated that over a 24-week treatment period, patients receiving '457 had similar improvements in global function and cognitive function compared to patients receiving donepezil.

These data demonstrate the potential of '457 for use in the treatment of Alzheimer's disease. Two large phase II trials investigating the potential of '457 as monotherapy and as adjunctive therapy in patients with mild-to- moderate Alzheimer's disease are expected to start next year.

Also for the treatment of Alzheimer's disease, initial results from the ongoing phase III development program for rosiglitazone XR are anticipated in 2009. Rosiglitazone XR is being studied as monotherapy, compared with donepezil and placebo. Two additional phase III studies with rosiglitazone XR as an adjunct therapy are ongoing.

1838262 - Potential new treatment for RLS, neuropathic pain and migraine:

Neuropathic pain is caused by nerve injury resulting from conditions such as shingles and diabetes. Gabapentin is one of the most widely used treatments for neuropathic pain; however it is only effective in some patients. GSK, in collaboration with XenoPort, is developing a new chemical entity, 1838262 (XP13512), which utilizes a novel transport mechanism to enable '262 to be efficiently absorbed into the body where it is converted to gabapentin. The improved drug exposure provided by '262 offers the potential for improved treatment of neuropathic pain and possibly other neurological disorders.

GSK and XenoPort are developing '262 for a number of different indications. The most advanced of these is for the treatment of restless legs syndrome (RLS). GSK expects to file '262 for use in this indication with the FDA in the third quarter of 2008.

As a result of published studies demonstrating that gabapentin has potential benefit in the prophylactic treatment of migraine attacks and chronic daily headaches, together with the fav
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
9. Pharmacopeia and GlaxoSmithKline Collaboration Identifies Two Additional Lead Compounds
10. Updated GOLD report presents new understandings in diagnosis, treatment and prevention of COPD
11. The Art Of Maternity(TM) at Destination Maternity(R) Presents A Sacred Passage Into Motherhood; the Art of Belly Masking to Belly Casting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2014)... Manufacturers of natural ingredient beauty creams are ... a younger appearance. The Cherry News company has published ... and women explore the availabilities from U.S. retailers at ... in the posted guide on the Cherry News website ... drawback to some natural ingredient formulas is the high ...
(Date:7/27/2014)... CA (PRWEB) July 27, 2014 Ticket Down ... Tickets at The Forum in Inglewood, California on November 15th. ... and diehard fans can expect to hear songs from this amazing ... of Summer concert in Inglewood, California at The Forum will be ... starting at 10:00 a.m. today local time TicketDown.com. This popular ...
(Date:7/27/2014)... The constant expansion of companies across the globe has ... Additional factors that have increased this demand include the ... communication, learning and development, security and safety, and knowledge ... enterprise video market value has crossed $11.21 billion in ... 2018 with a compound annual growth rate (CAGR) of ...
(Date:7/27/2014)... The report, “Oil Filter & Fuel Filter Market ... Type (OE & Aftermarket), Filter Type (Oil & Fuel), ... Trends & Forecast to 2018”, defines and segments the ... and forecasting of the global volume and revenue. The ... a revenue of $6.1 billion in 2018, while fuel ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 The European Bromine ... with analysis and forecast of revenue. , Bromine market in ... France, Spain, and UK. Germany and France that forms a ... and its derivatives in Europe. , Browse through the ... idea of the in-depth analysis provided Browse through the TOC ...
Breaking Medicine News(10 mins):Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:5 Seconds of Summer Tickets at The Forum in Inglewood (Los Angeles), CA Now Available For Sale at Ticket Down 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 2Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 3Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 4Health News:Oil Filter & Fuel Filter Market Worth $18.6 Billion by 2018 - Report by MarketsandMarkets 5Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bromine Market is Expected to Reach $111.6 Million in 2018 - New Report by MicroMarket Monitor 4
... risk factors for heart disease, including blood pressure and ... Association recommended Monday in new guidelines for the prevention ... the panel, observed that heart disease actually begins in ... make large changes in behavior early on. He said ...
... to a new research, a daily dose of a soybean ... "bad", or LDL, cholesterol levels in young men. Functional foods ... essential nutrients. //There has been a trend of adding value ... For example, Benecol Spread is a margarine that contains phytosterol ...
... Researchers say a daily teaspoon of lemon-flavored cod liver ... may help prevent middle ear infections in children. New ... infection,// required fewer antibiotics and had fewer ear infections ... oil, which has vitamins A and D and omega-3 ...
... Hopkins found a new study shows some cancer patients ... from treatment with the drug, interferon.,Past research has suggested ... B-cell non-Hodgkin's lymphoma's. //A patient with both of these ... patient responded causing researchers in Paris to study whether ...
... a new study which suggests hormone suppression therapy ... chances of living free of the disease.Michel Bolla, ... potential benefits of suppressing the male hormone androgen, ... testosterone, among 400 patients in advanced stages// of ...
... to take antibiotics before dental cleaning to reduce the ... drugs do not take them, sometimes because their doctors ... realize that the antibiotics are warranted, according to a ... that they say may increase compliance with the antibiotic ...
Cached Medicine News:Health News:Heart attack risk starts at 20 2Health News:Hormone Therapy applicable for Prostate Cancer 2
(Date:7/25/2014)... Dr. Michael Gabriel of a prominent Staten ... study, which shows how grief in pregnancy may cause obesity ... According to US News , "Unborn children ... others to grow up overweight or obese, even if that ... specific types of stress that caused obesity: "Children whose biological ...
(Date:7/24/2014)... , July 24, 2014  Restore Health, ... and compounded pharmaceuticals, announced that it is now ... unique to each individual based upon their particular ... by understanding the interaction between a patient,s genetics ... "We,re very excited to provide this new service ...
(Date:7/24/2014)... Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... blood analysis systems, today reported financial results for the ... First quarter overview: , Revenues of $47.5 million, ... Diluted EPS of $0.21, up 50% over last year,s ... market revenues of $7.2 million, up 20% over last ...
Breaking Medicine Technology:Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Bioness Inc., today announced the commercial release of its ... Drug Administration (FDA) earlier this year, the L300 Plus combines ... thigh cuff to activate even more of the nerves and ... The L300 Plus is intended for people ...
... LLC , a drug research and development company focused ... its compound CM-182 demonstrated positive results for reduction in ... screening was performed by the contract research organization, Cerca ... C57BL/6 mice exhibited a dose dependent reduction in hyperactivity ...
Cached Medicine Technology:Bioness Inc Announces Availability of L300 Plus System 2Curemark Reports Positive Results for Novel Compound CM-182 in Amphetamine Induced Hyperactivity 2
... agitators offer a wide range of storage ... drawer storage platform to agitate smoothly, eliminating ... down and squeak. Sturdy, one-piece perforated drawers ... circulation for your platelets., ,i.Series platelet agitators ...
Platelet agitator....
The "s" series shakers are available in orbital, reciprocating and Blood Bank Platelet versions....
The "s" series shakers are available in orbital, reciprocating and Blood Bank Platelet versions....
Medicine Products: